Stage 4 Ovarian Cancer Care: Treatment & Expert Insights

What is Stage 4 Ovarian Cancer?

Stage 4 ovarian cancer is the most advanced form of the disease, characterized by distant metastases beyond the peritoneal cavity. This stage occurs in about 30% of diagnoses, with a 5-year survival rate of only 17-25% despite maximal therapy. According to FIGO staging, Stage 4 is divided into two categories:

• •Stage 4A
  Involves positive pleural cytology due to malignant ascites or effusion (the most common presentation), and liver surface metastases without parenchymal invasion.
• •Stage 4B
  Includes parenchymal metastases to the liver or spleen, intestinal serosal metastases outside the pelvis, extra-abdominal lymph nodes (such as inguinal or supraclavicular), or lung and other distant organ spread.

Causes and Risk Factors of Stage 4 Ovarian Cancer

The causes and risk factors for Stage 4 ovarian cancer mirror those of earlier stages. This includes genetic factors such as BRCA1/2 mutations and Lynch syndrome, age over 60 years (with a peak incidence), and high-grade serous histology, which accounts for 90% of Stage 4 cases. Stage 4 often results from undetected peritoneal dissemination followed by hematogenous spread. Additionally, aggressive biological features, such as TP53 mutations and CCNE1 amplification, are present in 70-80% of high-grade serous carcinomas.

Signs and Symptoms of Stage 4 Ovarian Cancer

• •Common Early Signs
  Marked abdominal distension due to massive ascites (90%), early satiety and nausea, weight loss, and bilateral leg edema resulting from inferior vena cava compression.
• •Less Common Symptoms
  Dyspnea due to pleural effusion (Stage 4A), jaundice from liver metastases, seizures due to brain metastases (less than 1%), and palpable supraclavicular Virchow’s node indicating abdominal progression.

Diagnosis of Stage 4 Ovarian Cancer

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

• •Biomarkers and Imaging
  Elevated CA-125 levels (greater than 1000 U/mL) and PET-CT scans showing FDG-avid distant lesions in the liver, omentum, or lymph nodes.
• •Procedural Diagnosis
  Diagnostic thoracentesis to confirm malignant pleural effusion and diagnostic laparoscopy to assess the feasibility of cytoreduction using the Peritoneal Cancer Index (PCI) scoring system.
• •Tissue Analysis
  A tissue biopsy can confirm carcinoma, and comprehensive genomic profiling (assessing homologous recombination deficiency, microsatellite instability, and NTRK status) can guide therapy despite the palliative intent.

Treatment Process for Stage 4 Ovarian Cancer

• •Primary Systemic Therapy
  Neoadjuvant therapy with carboplatin and paclitaxel ± bevacizumab (as per GOG-218) is administered for 3-4 cycles followed by interval cytoreduction if there is a response (greater than 90% decline in CA-125 and reduction in PCI).
• •Palliative Cytoreduction
  Secondary debulking surgery is considered for responders to relieve symptoms, such as controlling ascites and preventing bowel obstruction. Complete remission (R0) is rare, occurring in less than 20% of cases.
• •Maintenance Therapy
  PARP inhibitors (niraparib or olaparib) are given to BRCA/HRD-positive patients (PRIMA trial). Pembrolizumab is used for the MSI-high subset, and participation in clinical trials for antibody-drug conjugates is encouraged.

Why Choose Everhope for Stage 4 Ovarian Cancer Treatment?

Everhope Oncology offers genomic-driven palliative regimens that achieve a good radiographic response rate. The symptom-directed cytoreduction aims to prevent hospitalizations, and IV nutritional support maintains performance status, thereby enhancing trial eligibility and improving the quality of life.